-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
NEXIEN BIOPHARMA, INC. quarterly and annual Earnings Per Share, Diluted history and change rate from 2022 to Q1 2025.
- NEXIEN BIOPHARMA, INC. Earnings Per Share, Diluted for the quarter ending 31 Mar 2025 was 0, unchanged year-over-year.
- NEXIEN BIOPHARMA, INC. Earnings Per Share, Diluted for the twelve months ending 31 Mar 2025 was 0.
- NEXIEN BIOPHARMA, INC. annual Earnings Per Share, Diluted for 2024 was 0.
- NEXIEN BIOPHARMA, INC. annual Earnings Per Share, Diluted for 2023 was -0.01, unchanged from 2022.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Change (%)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Change (%)